Immunotherapy
25 videos · last 6 months shuffled daily, then older videos newest first
▶
6:20 MONVISO: Etentamig Efficacy by Prior BCMA Therapy
Saurabh Chhabra, MBBS, MS, of Mayo Clinic Arizona describes how efficacy of etentamig, a BCMA x CD3 bispecific, varied by prior BCMA-targeting therapy in the phase 1b MONVISO study presented at ASCO 2026, for Blood Cancers Today.
▶
8:32 MONVISO: Etentamig Safety in Relapsed Multiple Myeloma
Saurabh Chhabra, MBBS, MS, of Mayo Clinic Arizona discusses safety results from the phase 1b MONVISO study of etentamig, a BCMA x CD3 bispecific, in relapsed or refractory multiple myeloma, for Blood Cancers Today.
▶
16:56 Small Cell Lung Cancer Research: Dr. Ashish Saxena
Dr. Ashish Saxena, Chief of Thoracic Medical Oncology at Weill Cornell Medicine, discusses small cell lung cancer trials for Lung Cancer Foundation of America, covering patient-reported outcomes and immunotherapy and antibody drug conjugate research.
▶
1:55 KEYNOTE-522 Update for Triple-Negative Breast Cancer
Dr. Bill Gradishar explains the seven-year KEYNOTE-522 update in triple-negative breast cancer, which showed continued event-free and overall survival benefits with longer follow-up, for Yerbba.
▶
6:55 LINKER-SMM1 Assesses Linvoseltamab for High-Risk Smoldering Multiple Myeloma
Paula Rodríguez-Otero, MD, PhD, of the University of Navarra, lead author of the phase 2 LINKER-SMM1 trial, discusses safety and efficacy results for linvoseltamab in high-risk smoldering multiple myeloma, including a May 2026 update, for Blood Cancers Today.
▶
9:32 IRAKLIA: Isatuximab Results by Prior Anti-CD38 Therapy
Sikander Ailawadhi, MD, of the Mayo Clinic Comprehensive Cancer Center discusses a post hoc analysis of the phase 3 IRAKLIA trial of isatuximab with pomalidomide and dexamethasone by prior anti-CD38 therapy, presented at ASCO 2026, for Blood Cancers Today.
▶
2:55 IMMUNO-BIOMAP: Predicting Immunotherapy Response in NSCLC
Ravi Salgia, MD, PhD, of City of Hope explains the biomarker-driven design of IMMUNO-BIOMAP, an ARPA-H-funded phase 2 trial aiming to enrol 535 patients with metastatic NSCLC to predict who benefits from first-line immunotherapy, for Targeted Oncology.
▶
53:52 The TIME Trial: Does Immunotherapy Timing Matter in Melanoma?
Dr. Omid Hamid of The Angeles Clinic, Dr. Ryan Sullivan of Massachusetts General Hospital and colleagues explain the TIME Trial, testing whether earlier-in-the-day immunotherapy affects outcomes in advanced melanoma, for the Melanoma Research Alliance.
▶
16:22 CoRegen on Engineered Tregs for Solid Tumors
Sonal Gupta, MD, PhD, Chief Medical Officer of CoRegen, discusses the company's investigational engineered Treg cell therapy CRG150 for solid tumors, its move into first-in-human studies and CDMO selection, on Life Science Connect's Cell & Gene: The Podcast.
▶
5:48 SCIENCE Trial: Neoadjuvant Sintilimab in Oesophageal Cancer
Dr Xuefeng Leng reviews phase III SCIENCE trial results with ecancer at ASCO 2026, in which neoadjuvant chemoradiotherapy plus sintilimab improved pathological complete response in resectable locally advanced oesophageal squamous cell carcinoma.
▶
4:30 POLE Mutations as Predictive Biomarkers for Immunotherapy in GI Cancers
Umair Mahmood, BSc, MSc, University College London Hospital, London, UK, discusses the potential of POLE mutations as predictive biomarkers for immune checkpoint inhibitor therapy in gastrointestinal cancers.
▶
10:29 MonumenTAL-6 Results in Relapsed/Refractory Myeloma
Ajay K. Nooka, MD, MPH, of Emory University School of Medicine discusses topline results from the phase 3 MonumenTAL-6 trial of teclistamab plus talquetamab, or talquetamab plus pomalidomide, in relapsed/refractory multiple myeloma, for CheckRare.
▶
52:06 The Latest Therapeutic Developments for Type 1 Diabetes Post-ADA
Piper Sandler analyst Ted Tenthoff and Joslin Diabetes Center's Dr. Rohit Kulkarni discuss type 1 diabetes data from ADA 2026, including teplizumab, beta cell regeneration and menin inhibition.
▶
34:37 Kidney Cancer Research Summit Rapid Abstracts, Part One
Investigators present kidney cancer research at the 2026 Kidney Cancer Research Summit, including long-term OMNIVORE trial follow-up of response-adaptive nivolumab and ipilimumab and updated Phase 1a FIT-001 results.
▶
1:14 BATTMAN Trial: Botensilimab and Balstilimab in MSS mCRC
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, describes the study design of the Phase III BATTMAN trial (NCT07152821), which will examine botensilimab plus balstilimab versus best supportive care in hepatic and non-hepatic microsatellite stable metastatic colorectal cancer (MSS mCRC).
▶
1:40 frontMIND: Tafasitamab Plus R-CHOP in High-Risk DLBCL
At ASCO 2026, Dr Georg Lenz discusses phase III frontMIND results with ecancer, in which tafasitamab plus lenalidomide and R-CHOP improved progression-free and event-free survival over R-CHOP alone in high-risk DLBCL and HGBL.
▶
29:12 Dr. Ibiayi Dagogo-Jack Joins MesoTV to Discuss Immunotherapy and Clinical Trials for Mesothelioma
Dr. Ibiayi Dagogo-Jack of the Massachusetts General Hospital discusses immunotherapy treatments and clinical trials, including several new precision medicine clinical trials, for mesothelioma with MesoTV .
▶
2:25 Study At UC Davis Looks at Whether Treating Cancer in Dogs Can Help Humans With Cancer
UC Davis Comprehensive Cancer Center and the UC Davis Veterinary Medicine Center are conducting a new immunotherapy clinical trial to treat cancer in dogs because they hope that the results will be used to help humans with cancer.
▶
3:56 A Doctor’s Perspective on IN8bio’s Trial Results
Dr. Burt Nabors of UAB discusses IN8bio's gamma-delta T cell trial results in glioblastoma and how the approach differs from others.
▶
21:22 Lilla Lördag – Diamyd Medical
Ulf Hannelius, CEO of Diamyd Medical, on precision immunotherapies targeting the autoimmune process behind type 1 diabetes, and the Phase 3 trial of retogatein ahead of a March 2026 interim readout.
▶
2:35 Breast Cancer Trials Clinical Fellowship Program - Dr Julia Dixon-Douglas
Dr Julia Dixon-Douglas on UNRAVEL-TNBC, her Breast Cancer Trials fellowship project into what drives response and resistance to immunotherapy in early-stage triple negative breast cancer.
▶
2:05 UC Davis Clinical Trial Participant with Stage 4 Cancer Discusses Clinical Trials
A patient with follicular lymphoma, a form of cancer, has been on a clinical trial for eight years which is over 100 doses of immunotherapy.
▶
16:13 INOVIO DNA Immunotherapy and GBM
Dr. Jeffrey Skolnik, Inovio's VP of Clinical Development, Oncology, talks to Dr. David Reardon of Dana-Farber, coordinating principal investigator of GBM-001/INO-5401, about DNA immunotherapy in glioblastoma.
▶
2:20 Peanut Allergy Clinical Trials
A clinical trial involving immunotherapy and immunotherapy plus a probiotic for peanut allergies is explored in this video.